The Motley Fool
18 Oct 2026, 21:13 UTC · 1h ago
Where Will CRISPR Therapeutics Stock Be in 2030?
Impact · against what's priced in
The article provides no new catalysts for CRSP or VRTX, as the clinical progress for CTX310 and the commercialization of Casgevy are already recognized by the market. Because the price for CRSP explicitly declines the pipeline's current success, simply reiterating known Phase 1 data does not shift the valuation.
- CRSP+0.00
Already priced in
- The price assumes
The cardiovascular and autoimmune pipeline data (CTX310's 50% lipid reductions...)
The article highlights CTX310's Phase 1 data showing significant decreases in LDL and triglycerides, but the market is already aware of these results and continues to decline the pipeline's potential upside.
What CRSP's price assumes · Sep 5
